Chemotherapy-Induced Neuropathy in Cancer Survivors

Miaskowski, Christine; Mastick, Judy; Paul, Steven M.; Topp, Kimberly; Smoot, Betty; Abrams, Gary; Chen, Lee-may; Kober, Kord M.; Conley, Yvette P.; Chesney, Margaret A.; Bolla, K.; Mausisa, Grace; Mazor, Melissa; Wong, Melisa L.; Schumacher, Mark; Levine, Jon D.

doi:10.1016/j.jpainsymman.2016.12.342

Cited by 106 publications

(96 citation statements)

References 99 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A total of 122 participants declined participation, and 67 did not complete the questionnaire. The study group consisted of 285 survivors of cancer during adolescence and young adulthood, with the mean age of 28 (range [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35], and the control group consisted of 255 participants with the mean age of 28 (range [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. There were no differences between the groups, except regarding education, where the controls had a significantly higher educational level than the cancer survivors.…”

Section: Resultsmentioning

confidence: 99%

“…Having less frequent orgasm orgasms could lead to feeling less satisfied with sexual function. In studies on cancer survivors, one long-term effect is peripheral neuropathy in the extremities, and among female diabetes patients, having vascular damage and neuropathy may result in decreased genital blood flow and cause genital arousal, orgasm [32,33]. Whether difficulties having less frequent orgasm are due to physical or psychological effects needs further research, including more detailed information on cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Sexual function in adolescent and young adult cancer survivors—a population-based study

et al. 2018

View full text Add to dashboard Cite

Purpose Previous research has established that treatments for cancer can result in short-and long-term effects on sexual function in adult cancer patients. The purpose was to investigate patient-reported physical and psychosexual complications in adolescents and young adults after they have undergone treatment for cancer. Methods In this population-based study, a study-specific questionnaire was developed by a method used in several previous investigations carried out by our research group, Clinical Cancer Epidemiology. The questionnaire was developed in collaboration with adolescent and young adult cancer survivors (15-29 years) and validated by professionals from oncology units, midwives, epidemiologists, and statisticians. The topics covered in the questionnaire were psychosocial health, body image, sexuality, fertility, education, work, and leisure. The web-based questionnaire was sent to adolescent and young adult cancer survivors and matched controls in Sweden. Results In this study, adolescent and young adult cancer survivors (15-29 years) showed low satisfaction regarding sexual function compared to controls (P < 0.01). Female adolescent and young adult cancer survivors had a statistically significant lower frequency of orgasm during sexual activity than the controls (P < 0.01). Male adolescent and young adult cancer survivors had statistically significant lower sexual desire than the controls (P = 0.04). Conclusions We found that adolescent and young adult cancer survivors perceived themselves as being less satisfied with their sexual function than matched population-based controls. Implications for Cancer Survivors Adolescent and young adult cancer survivors need psychological rehabilitation support from the health care profession during and after cancer treatment to help them to reduce their reported poor sexual function to enhance a good sexual quality of life.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Sexual function in adolescent and young adult cancer survivors—a population-based study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Potential risk factors identified previously in the literature (Armstrong et al, ; Hauseer et al, ; Kaley & DeAngelis, ; Miaskowski et al, ; Ottaiano et al, ; Quasthoff & Hartung, ) were examined for their impact in the development of CIPN. These included: Diagnosis with acquired or hereditary neuropathy such as diabetes, renal disease, hypothyroidism, connective tissue disease.…”

Section: Outcome Measuresmentioning

confidence: 99%

“…Being obese and having more insomnia severity, anxiety, and depression were all associated with CIPN in other studies (Bao et al, ; Simon, Danso, Alberico, Basch, & Bennett, ). Older age, lower income, higher BMI, comorbidities, being born prematurely, higher cumulative dose of chemotherapy, and poorer functional status were also predictive of CIPN (Miaskowski et al, ). Diabetes was also shown to be predictor of CIPN (Ottaiano et al, ) although other studies have found no such link (Pereira et al, ; Simon et al, ).…”

Section: Introductionmentioning

confidence: 99%

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy

Molassiotis

Cheng

Leung³

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

Background Chemotherapy‐induced peripheral neuropathy (CIPN) is a significant and difficult to manage side effect of neurotoxic chemotherapies. Several risk factors for CIPN have been identified to date, but inconsistencies and methodological limitations exist in past research. Also, a limited number of potential risk factors has been investigated in the past. Aim The objective of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN. Methods This analysis used the 6‐month data after starting chemotherapy from a larger prospective observational study on CIPN risk, prevalence, and quality of life. Patients were assessed at recruitment for possible CIPN risk factors, including prior history of neuropathies, current/past infectious diseases; neurotoxic medication history; personal and treatment characteristics; smoking history, alcohol use, and vegetable/fruit intake. Neuropathy was assessed at 6‐months after starting chemotherapy with the neuropathy (motor/sensory) items of the NCI‐CTCAE scale and the WHO criterion for neuropathy. Data on symptom burden were also collected. Results Data were available from 255 patients from three cancer centers in Hong Kong, Singapore, and UK. The use of different scales did not always identify the same predictor variables. Key risk factors in multivariate regression models included older age (highest OR = 1.08, p < 0.01 with the WHO scale), chemotherapy (platinum‐based chemotherapy had OR = 0.20–0.27 in developing CIPN compared to taxane‐based chemotherapy), history of neuropathy (for motor CIPN only, OR = 8.36, p < 0.01), symptom burden (OR = 1.06, p < 0.05), number of chemotherapy cycles received (OR = 1.19–1.24, p < 0.01), and alcohol intake (OR = 0.32, p < 0.05). In univariate analysis, the use of statins was implicated with CIPN ( p = 0.03–0.04 with different assessments) and diabetes showed a trend ( p = 0.09) in the development of CIPN. Conclusion This study confirmed the CIPN risk related to certain variables and identified new ones. This knowledge can assist with treatment decisions and patient education.

show abstract

“…Decreased distal lower extremity strength and loss of sensation, including proprioception, are risk factors for increased falls and balance deficits [8–12]. Patients who undergo treatment with taxane drugs and/or develop CIPN often present with decreased postural stability [13–18,11]. Recent research suggests that CIPN may also be associated with functional impairments during ambulation [19].…”

Section: Introductionmentioning

confidence: 99%

Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients

Monfort

Pan

Patrick

et al. 2017

Breast Cancer Res Treat

106

View full text Add to dashboard Cite

BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several commonly used chemotherapy drugs including taxanes, vinca alkaloids, and platinum compounds. Development of CIPN is highly variable, both in self-reported symptoms and functional consequences, and can be severe enough to alter dose intensity. PURPOSE To describe the natural histories of both patient-reported symptoms of chemotherapy-induced peripheral neuropathy (CIPN) and functional impairments in breast cancer patients undergoing taxane-based chemotherapy. METHODS Thirty-three breast cancer patients (32 female/1 male; 47.8 ± 11.2 years; n=17 stage II/n=16 stage III) were enrolled. Patients completed self-reports of symptoms and function (e.g., EORTC QLQ-CIPN20) and objective measures of physical function (i.e., balance and gait testing) in an outpatient oncology clinic at five timepoints: (1) baseline - prior to starting chemotherapy, (2–4) before starting subsequent chemotherapy cycles, and (5) 1–3 months after receiving their last taxane infusion. RESULTS Significant negative changes in both patient-reported outcomes and objective functional measures were observed. Decreased balance was observed after the first chemotherapy cycle (28% increase in medial-lateral excursion of the center of pressure, p=0.016) and progressed with cumulative exposure (43% increase, p<0.001). Patients also demonstrated slower walking speeds (5% decrease, p=0.003) as they progressed through treatment. These functional deficits were mirrored with increased patient-reported symptom severity for all EORTC QLQ-CIPN20 subscales (all p<0.05). CONCLUSION This study longitudinally assessed patient-reported outcomes concurrently with balance and gait testing in patients undergoing taxane therapy. Taxane treatment was associated with the development of clinically-relevant problems in both CIPN symptoms and patient function.

show abstract

Chemotherapy-Induced Neuropathy in Cancer Survivors

Cited by 106 publications

References 99 publications

Sexual function in adolescent and young adult cancer survivors—a population-based study

Sexual function in adolescent and young adult cancer survivors—a population-based study

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy

Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients

Contact Info

Product

Resources

About